Payment overview · 2025
General Payments
$2,761.94
103 reported records · 13 companies
Healthcare provider profile · identity verified
Josiah Keaton Aldrup
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health · HUNTSVILLE, AL · NPI 1184165748
Verified facts
What the public records show
CMS Open Payments records show Josiah Keaton Aldrup received $2,761.94 in general payments during 2025 across 103 reported records.
Alkermes, Inc. accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abilify Maintena, Aristada, Austedo Xr, Fanapt, Invega Sustenna, Lybalvi, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUPRON DEPOT as an associated drug or biological on 6475 records involving 3205 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lupron Depot by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lybalvi by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Invega Sustenna by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Austedo Xr by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UZEDY as an associated drug or biological on 46702 records involving 13355 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Uzedy by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $702.56 | 25.4% | 21 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $365.40 | 13.2% | 11 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $330.41 | 12.0% | 8 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $291.12 | 10.5% | 14 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $286.58 | 10.4% | 14 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $187.66 | 6.8% | 7 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $174.65 | 6.3% | 13 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.26 | 4.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $89.23 | 3.2% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.43 | 2.9% | 4 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $58.00 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $55.08 | 2.0% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $16.56 | 0.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,703.94 | 102 |
| Honoraria | $58.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $579.50 | 20 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $577.57 | 20 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $365.40 | 11 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $313.06 | 7 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $291.12 | 14 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $218.60 | 9 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $187.66 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $174.65 | 13 | 2025 |
Source payment records
|
|||||
| ARISTADA INITIO Normalized: aristada initio |
Drug | Alkermes, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $124.26 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $89.23 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.43 | 4 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $67.98 | 5 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Otsuka America Pharmaceutical, Inc. | $55.48 | 4 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $55.08 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $16.56 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABILIFY MAINTENA abilify maintena |
2025 | Abilify Maintena | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ARISTADA aristada |
2025 | Aristada | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 90 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 122 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUPRON DEPOT open payments reported associated product |
CMS Open Payments — General Payments 6475 supporting records · 3205 recipient NPIs · example record 1201352804 |
Lupron Depot · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
122 | 17 |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | UZEDY open payments reported associated product |
CMS Open Payments — General Payments 46702 supporting records · 13355 recipient NPIs · example record 1247244226 |
Uzedy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clonazepam | Clonazepam | 1112 | 119 |
| Trazodone Hcl | Trazodone Hcl | 893 | 120 |
| Olanzapine | Olanzapine | 678 | 43 |
| Benztropine Mesylate | Benztropine Mesylate | 602 | 50 |
| Quetiapine Fumarate | Quetiapine Fumarate | 594 | 72 |
| Risperidone | Risperidone | 542 | 41 |
| Aripiprazole | Aripiprazole | 488 | 66 |
| Buspirone Hcl | Buspirone Hcl | 482 | 63 |
| Divalproex Sodium Er | Divalproex Sodium | 481 | 37 |
| Sertraline Hcl | Sertraline Hcl | 462 | 53 |
| Alprazolam | Alprazolam | 446 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 376 | 40 |
| Lorazepam | Lorazepam | 367 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 335 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 325 | 65 |
| Mirtazapine | Mirtazapine | 308 | 43 |
| Lamotrigine | Lamotrigine | 299 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 288 | 23 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 233 | suppressed |
| Diazepam | Diazepam | 225 | 26 |
| Divalproex Sodium | Divalproex Sodium | 211 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 196 | 30 |
| Lithium Carbonate | Lithium Carbonate | 193 | 19 |
| Gabapentin | Gabapentin | 192 | 16 |
| Haloperidol | Haloperidol | 192 | 16 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 174 | 14 |
| Ziprasidone Hcl | Ziprasidone Hcl | 162 | 15 |
| Bupropion Xl | Bupropion Hcl | 137 | 35 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 132 | 29 |
| Vraylar | Cariprazine Hcl | 122 | 17 |
| Prazosin Hcl | Prazosin Hcl | 120 | 23 |
| Oxcarbazepine | Oxcarbazepine | 115 | 21 |
| Carbamazepine | Carbamazepine | 112 | suppressed |
| Clozapine | Clozapine | 107 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 97 | 14 |
| Topiramate | Topiramate | 96 | 12 |
| Paliperidone Er | Paliperidone | 93 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 90 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 79 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 77 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 70 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 64 | 12 |
| Guanfacine Hcl | Guanfacine Hcl | 63 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 62 | 18 |
| Fluphenazine Hcl | Fluphenazine Hcl | 61 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 61 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Abilify Maintena | Aripiprazole | 53 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 12 |
| Austedo | Deutetrabenazine | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 47 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 43 | suppressed |
| Austedo Xr | Deutetrabenazine | 42 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 41 | suppressed |
| Rexulti | Brexpiprazole | 41 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 40 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 39 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 32 | suppressed |
| Aristada | Aripiprazole Lauroxil | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 27 | suppressed |
| Lacosamide | Lacosamide | 26 | suppressed |
| Olanzapine Odt | Olanzapine | 26 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 22 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 18 | suppressed |
| Uzedy | Risperidone | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Risperidone Odt | Risperidone | 17 | suppressed |
| Dayvigo | Lemborexant | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Lupron Depot | Leuprolide Acetate | 13 | suppressed |
| Fanapt | Iloperidone | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,761.94 · 103 records | Alkermes, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Azstarys, CAPLYTA, COBENFY, FANAPT, INGREZZA, INVEGA SUSTENNA, Jornay PM, LYBALVI, Qelbree, REXULTI, SPRAVATO, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abilify Maintena play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error